/
Unless context requires otherwise, references to we, us, our, BillionToOne, or the Company here refer to BillionToOne, Inc. Overview BillionToOne is transforming healthcare by redefining molecular diagnostics.
Operating margin is thin at 5.25%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 100.0% YoY with margins expanding 36.2pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$375M
▲ +100.0% YoY
Net Income (TTM)
$40M
▲ +117.9% YoY
Op. Margin
12.39%
▲ +36.2pp YoY
ROIC
11.69%
▲ +72.6pp YoY
Cash Flow & Balance Sheet
FCF (FY)
$16M
▲ +133.6% YoY
Op. Cash Flow (FY)
$25M
▲ +159.4% YoY
Net Debt
-$393M
Net Cash Position
Cash & Equiv.
$537M
Continue Research